Latest Insights

Looking for hidden opportunities in global pharma? Our insights reveal them.

All Deal Intelligence Market Analysis Strategic Guides Regional Guides Company & Capital NewCo Formation

Biotech Investment Banking: The Complete Guide for 2026

Company & Capital

March 1, 2026

Biotech Investment Banking: The Complete Guide for 2026

Complete guide to biotech investment banking: top life science IB firms, deal types (M&A, IPO, licensing), valuation methods, and how to choose the right advisor for your transaction.

China Clinical Trials: Cost, Speed & Regulatory Advantages

Regional Guides

February 28, 2026

China Clinical Trials: Cost, Speed & Regulatory Advantages

Run clinical trials in China and save 60% on costs with 2-5x faster enrollment. NMPA IND process, MRCT strategy for FDA acceptance, BIOSECURE Act clarification, and China CRO landscape guide.

NMPA Drug Approval Process: Complete Guide 2026

Regional Guides

February 28, 2026

NMPA Drug Approval Process: Complete Guide 2026

China's FDA equivalent explained. Complete guide to NMPA drug approval pathways, IND filing, Breakthrough Therapy Designation, Conditional Approval, and NDA timelines for global pharma companies.

Clinical Trial Patient Enrollment: Strategies to Accelerate Recruitment

Strategic Guides

February 28, 2026

Clinical Trial Patient Enrollment: Strategies to Accelerate Recruitment

80% of trials miss enrollment deadlines. Evidence-based strategies for faster patient recruitment — including why China's 2-5x faster enrollment advantage is transforming global drug development timelines.

In-Licensing China Biotech Assets: Strategic Guide 2026

Strategic Guides

February 28, 2026

In-Licensing China Biotech Assets: Strategic Guide 2026

A practical playbook for Western BD executives on scouting, evaluating, and acquiring Chinese biotech innovation. Due diligence, deal structuring, NMPA data strategy, and BIOSECURE compliance covered.

Top Chinese Biotech Companies to Watch in 2026

Regional Guides

February 28, 2026

Top Chinese Biotech Companies to Watch in 2026

The definitive guide to China's most innovative biotech companies with active out-licensing pipelines. ADC, bispecific, GLP-1, CAR-T leaders and their global deal pipelines — organized by therapeutic area.

Life Sciences M&A 2026: Trends & Strategic Analysis

Deal Intelligence

February 28, 2026

Life Sciences M&A 2026: Trends & Strategic Analysis

$280B+ projected deal value. Patent cliff urgency, AI-driven targets, and Asia's emergence as a deal epicenter are reshaping the M&A landscape for life sciences executives.

Biotech Venture Capital 2026: Definitive Investor Guide

Company & Capital

February 28, 2026

Biotech Venture Capital 2026: Definitive Investor Guide

$38B deployed in 2025. Top VC firms, investment stages, therapeutic area preferences, geographic trends, and the NewCo/platform creation trend reshaping biotech funding.

Life Sciences Consulting: The Complete Guide for 2026

Strategic Guides

February 28, 2026

Life Sciences Consulting: The Complete Guide for 2026

Comprehensive guide to life sciences consulting: types of services, when pharma and biotech companies need it, how to choose a firm, and 2026 industry trends.

Top Life Sciences Consulting Firms 2026: Complete Guide

Strategic Guides

February 28, 2026

Top Life Sciences Consulting Firms 2026: Complete Guide

Compare MBB, Big 4, mid-size specialists, and boutique deal advisors. A strategic guide to choosing the right life sciences consulting firm for your needs.

Biotech Partnerships: Types, Structures & How They Work

Strategic Guides

February 28, 2026

Biotech Partnerships: Types, Structures & How They Work

A guide to biotech partnership models including co-development, platform licensing, and equity alliances.

Market Analysis

February 28, 2026

CDMO Market Analysis 2026: Size, Trends & Key Players

Comprehensive CDMO market analysis covering market size, key players, selection criteria, and outsourcing trends.

Biotech Licensing Deal Tracker 2026: Top Deals, Trends & Strategic Analysis

Deal Intelligence

February 16, 2026

Biotech Licensing Deal Tracker 2026: Top Deals, Trends & Strategic Analysis

$250B+ across 516 licensing deals in 2025. Average deal size surges 76% in 2026. Track the biggest transactions and what they mean for your BD strategy.

Gene Therapy Market 2026: Approved Products, Pipeline & Licensing Deals

Market Analysis

February 16, 2026

Gene Therapy Market 2026: Approved Products, Pipeline & Licensing Deals

Zolgensma ($1.24B), Elevidys ($820M+), and CRISPR-based Casgevy are transforming rare disease. Track AAV, CRISPR, and in vivo gene therapy licensing opportunities.

Orphan Drug Designation & Rare Disease Licensing 2026: Market & Strategy Guide

Market Analysis

February 16, 2026

Orphan Drug Designation & Rare Disease Licensing 2026: Market & Strategy Guide

The $217B orphan drug market covers only 5% of rare diseases. 7-year exclusivity, premium pricing, and BioMarin's $4.8B Amicus deal signal massive BD opportunity.

ADC Market 2026: Antibody-Drug Conjugate Pipeline, Deals & Licensing

Market Analysis

February 16, 2026

ADC Market 2026: Antibody-Drug Conjugate Pipeline, Deals & Licensing

15 FDA-approved ADCs, $13.5B market, and Enhertu leading at $3.75B. Analysis of platform deals, China-origin assets, and licensing strategy for BD executives.

CAR-T Cell Therapy Market 2026: Products, Pipeline & Licensing Opportunities

Market Analysis

February 16, 2026

CAR-T Cell Therapy Market 2026: Products, Pipeline & Licensing Opportunities

The CAR-T market surpassed $5B with CARVYKTI growing 93% YoY. Allogeneic platforms, autoimmune expansion, and Lilly's $2.4B Orna deal reshape the landscape.

China Biotech Outbound Licensing Tracker 2026: $135.7B in Deal Value

Deal Intelligence

February 16, 2026

China Biotech Outbound Licensing Tracker 2026: $135.7B in Deal Value

Track every major China-to-global licensing deal. $135.7B cumulative value, AstraZeneca-CSPC $18.5B mega-deal, and BIOSECURE Act implications.

Biosimilars & Patent Cliff Licensing 2026: $100B+ Revenue at Risk

Market Analysis

February 16, 2026

Biosimilars & Patent Cliff Licensing 2026: $100B+ Revenue at Risk

Humira, Stelara, Keytruda — the biggest patent cliffs in pharma history are creating a $39.6B biosimilar market. Licensing guide for BD executives.

Pharma M&A Tracker 2026: Every Major Acquisition & What's Driving the Surge

Deal Intelligence

February 16, 2026

Pharma M&A Tracker 2026: Every Major Acquisition & What's Driving the Surge

$228B+ in pharma M&A in 2025. J&J-Intra-Cellular ($14.6B), Novartis-Avidity ($12B), and the patent cliff imperative reshaping deal strategy.

BeiGene: From China Biotech to Global Pharma Powerhouse

Company & Capital

February 16, 2026

BeiGene: From China Biotech to Global Pharma Powerhouse

$3.8B revenue in 2024, BRUKINSA surpassing Imbruvica, and a 50+ asset pipeline. How BeiGene became China's most successful global biotech.

PD-1/VEGF Bispecific Antibody Landscape 2026: Pipeline, Deals & Licensing

Market Analysis

February 16, 2026

PD-1/VEGF Bispecific Antibody Landscape 2026: Pipeline, Deals & Licensing

Ivonescimab's $5B Summit deal, HARMONi-2 data beating Keytruda, and 9+ pipeline candidates. The hottest bispecific antibody space in oncology.

The BIOSECURE Act: Impact on Pharma Supply Chains & China Partnerships

Regional Guides

February 16, 2026

The BIOSECURE Act: Impact on Pharma Supply Chains & China Partnerships

How the landmark legislation signed December 2025 reshapes global biopharma manufacturing, CDMO relationships, and cross-border deal strategy.

Pharma Deal Tracker 2026: The Definitive M&A & Licensing Roundup

Deal Intelligence

February 16, 2026

Pharma Deal Tracker 2026: The Definitive M&A & Licensing Roundup

$240 billion in life sciences M&A. $250 billion across 516 licensing deals. The biggest dealmaking year in pharma history—and what it means for 2026.

Drug Development Stages: The Complete Guide from Discovery to Approval

Strategic Guides

February 16, 2026

Drug Development Stages: The Complete Guide from Discovery to Approval

A definitive walkthrough of every stage in the pharmaceutical development process—with timelines, costs, success rates, and strategic deal implications.

Cross-Border Licensing Term Sheet Guide: Structuring Pharma Deals That Work

Strategic Guides

February 16, 2026

Cross-Border Licensing Term Sheet Guide: Structuring Pharma Deals That Work

A practical, clause-by-clause walkthrough of pharmaceutical licensing term sheets—with real-world benchmarks and China-specific negotiation strategies.

GLP-1 Licensing Landscape 2026: The Hottest Deal Space in Pharma

Market Analysis

February 16, 2026

GLP-1 Licensing Landscape 2026: The Hottest Deal Space in Pharma

$50 billion in deal value. 8+ mega-deals. The race for next-gen oral, monthly, and combination obesity treatments.

rNPV Valuation Guide: The Gold Standard for Pharma Asset Valuation

Strategic Guides

February 16, 2026

rNPV Valuation Guide: The Gold Standard for Pharma Asset Valuation

A practical, step-by-step guide to risk-adjusted NPV—the methodology behind every major pharma licensing deal and acquisition.

Biotech IPO & Funding Landscape 2026: The Window Reopens

Company & Capital

February 16, 2026

Biotech IPO & Funding Landscape 2026: The Window Reopens

The biotech IPO market surged back to life in late 2025. Track the biggest offerings, venture trends, and what makes a successful biotech IPO.

Pharma Due Diligence Checklist: The Complete Guide for Licensing & M&A

Strategic Guides

February 16, 2026

Pharma Due Diligence Checklist: The Complete Guide for Licensing & M&A

A comprehensive, practical checklist covering scientific, IP, regulatory, commercial, financial, and manufacturing due diligence for pharma deals.

Japan Pharma Market Entry Guide: Navigating the World's 3rd Largest Market

Regional Guides

February 16, 2026

Japan Pharma Market Entry Guide: Navigating the World's 3rd Largest Market

How to enter Japan's ~$90B pharmaceutical market. PMDA pathways, NHI pricing, partnership models, and cultural considerations.

Biotech M&A 2026: Navigating the $200B Patent Cliff

Company & Capital

December 23, 2025

Biotech M&A 2026: Navigating the $200B Patent Cliff

A technical analysis of valuation multiples and integration savings in the consolidation wave.

Pharma Business Development: The 2026 Definitive Guide

Strategic Guides

December 22, 2025

Pharma Business Development: The 2026 Definitive Guide

Transforming the BD function from a transactional support role into a core scientific strategy engine.

China Biotech Licensing 2026: The Definitive Technical Guide

Regional Guides

December 21, 2025

China Biotech Licensing 2026: The Definitive Technical Guide

Navigating the world's second-largest market: From NMPA acceleration to the ADC licensing surge.

NewCo Formation

December 20, 2025

NewCo Formation: The 2026 Strategic Blueprint

A definitive guide to biopharma asset-centric company formation and venture strategy.

In-Licensing vs Out-Licensing: The Complete Guide

Strategic Guides

December 19, 2025

In-Licensing vs Out-Licensing: The Complete Guide

A strategic framework for cross-border asset acquisition, monetization, and partnership structuring.